Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK Announces Offer to Repurchase Exchangeable Senior Notes Due 2023
GSK Finance (No.3) plc, is offering to repurchase for cash any and all of its outstanding Exchangeable Senior Notes due 2023.
-
ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine
Selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP
-
ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets
Findings show that cabotegravir LA for PrEP continued to demonstrate superior efficacy in the prevention of new HIV infections among women
-
GSK signs agreement to support pandemic preparedness in Europe
GSK will supply Adjupanrix to 12 participating European countries.
-
GSK delivers strong Q2 2022 sales of £6.9 billion +19% at AER, +13% at CER and Total EPS* from continuing operations** 17.5p -42% AER, -58% CER; Adjusted EPS of 34.7p +23% AER, +6% CER
Strong commercial execution across Specialty Medicines, Vaccines and General Medicines drives double-digit sales growth
-
ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022
Data to be presented include long-term and real-world data from portfolio of medicines
-
Board and Committee changes
Changes to GSK Board and Committees
-
Completion of GSK Share Consolidation
The consolidation of GSK shares will become effective at 8.00 a.m. tomorrow
-
Completion of the demerger of Haleon and share consolidation of GSK
Completion of the demerger of Haleon and share consolidation of GSK
-
GSK gathers global experts to discuss role of vaccines in protecting people and the planet
'Palio’ meeting to address growing threat to human health from infectious disease and its links to nature loss and climate change.
-
Result of General Meeting
At a General Meeting on Wednesday 6 July 2022 both resolutions set out in the Notice of General Meeting were duly passed by shareholders.
-
GSK completes acquisition of Sierra Oncology
GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.
-
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
GSK today announced the first recipient of the Target the Future Think Tank Challenge.
-
Japan’s Ministry of Health, Labour and Welfare accepts Shingrix regulatory submission to prevent shingles in at-risk adults aged 18 years and older
Shingrix was initially approved in 2018 by the Japanese MHLW to prevent shingles in adults aged 50 years or older
-
GSK presents promising new data for bepirovirsen, an investigational treatment for chronic hepatitis B
GSK today announced interim results from the B-Clear phase IIb trial at the EASL International Liver Congress.
-
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
First ever reported efficacy data in an Omicron environment support relevance of a Beta-containing vaccine
-
GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
GSK announced £1bn investment over ten years to accelerate R&D dedicated to infectious diseases
-
GSK to present new data from the B-Clear phase IIb trial for bepirovirsen in chronic hepatitis B at the International Liver Congress 2022
GSK will present 12 abstracts at the European Association for the Study of the Liver’s International Liver Congress 2022.
-
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
GSK today announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial.
-
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
